Brief: Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of Nereus™ For The Prevention Of Vomiting Induced By Glp-1 Receptor Agonists

Vanda Pharmaceuticals

08/04/2026 22:11

April 8 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:

VANDA PHARMACEUTICALS ANNOUNCES INITIATION OF THE THETIS STUDY, A CLINICAL TRIAL OF NEREUS™ FOR THE PREVENTION OF VOMITING INDUCED BY GLP-1 RECEPTOR AGONISTS

VANDA PHARMACEUTICALS INC - TOPLINE RESULTS FROM THETIS STUDY EXPECTED BY Q4 2026

VANDA PHARMACEUTICALS INC: PHASE 2 STUDY SUCCEEDED AND MET ITS PRIMARY ENDPOINT

Source text: ID:nPn7t1tgYa

Further company coverage: VNDA.O

 ((Reuters.Briefs@thomsonreuters.com;))